---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-012158"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:05:49.687703+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Galectin Therapeutics reports FY2025 net loss $31M; belapectin data for EASL upcoming

## Summary
- Net loss $31.0M ($0.48/share) vs $47.2M ($0.76) in 2024; R&D expense down to $14.3M from $36.6M.
- Cash $17.7M plus $10M credit line from chairman; runway through April 2027.
- Belapectin NAVIGATE trial: varices incidence reduced 49.3% in per-protocol (p=0.04); U.S. subgroup 68.1% (p=0.02).
- Additional biomarker data (FibroScan, ELF, PRO-C3) support antifibrotic activity; oral/poster presentations at EASL 2026.
- Upcoming FDA meeting in Q2 2026 to align on next steps; no approved therapy for MASH cirrhosis.

## SEC filing metadata
- accession: 0001140361-26-012158
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036126012158/0001140361-26-012158-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036126012158/ef20068722_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-012158
- JSON: https://secwatch.observer/filing/0001140361-26-012158.json
- Plain text: https://secwatch.observer/filing/0001140361-26-012158.txt

## Key facts
- Earnings Releases
  GALECTIN THERAPEUTICS INC reported financial results for the year ended December 31, 2025.
  - Period: the year ended December 31, 2025
  - Result: reported results
  source text: Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133416/000114036126012158/0001140361-26-012158-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.